CLBS - カラドリアス・バイオサイエンス (Caladrius Biosciences Inc.) カラドリアス・バイオサイエンス

 CLBSのチャート


 CLBSの企業情報

symbol CLBS
会社名 Caladrius Biosciences Inc (カラドリアス・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Hospital/Nursing Management  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis.   カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。   
本社所在地 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA
代表者氏名 David J. Mazzo デビットJ.マッツォ
代表者役職名 Chief Executive Officer Independent Director
電話番号 +1 908-842-0100
設立年月日 29465
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 221人
url https://www.caladrius.com/
nasdaq_url https://www.nasdaq.com/symbol/clbs
adr_tso
EBITDA EBITDA(百万ドル) -22.53046
終値(lastsale) 5.01
時価総額(marketcap) 48724464.42
時価総額 時価総額(百万ドル) 44.34802
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -5.95137
当期純利益 当期純利益(百万ドル) 13.58047
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95.

 CLBSのテクニカル分析


 CLBSのニュース

   54 Biggest Movers From Yesterday - Stocks News Feed  2021/01/21 10:03:57 Stocks News Feed
Gainers Obalon Therapeutics Inc (NASDAQ: OBLN) shares jumped 414.3% to close at $8.28 on Wednesday after the company announced a merger agreement with ReShape Lifesciences. Steel Connect, Inc. (NASDAQ: STCN) gained 79.2% to close at $2.67 after climbing over 36% on Tuesday. Caladrius Biosciences, Inc. (NASDAQ: CLBS) shares gained 77.3% to close at $2.89. Caladrius… Read More »54 Biggest Movers From Yesterday
   Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp?  2021/01/20 15:45:00 PR Newswire
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLBS, NIO, BIOL, FCEL, and CCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   CLBS Stock: Caladrius Biosciences Squeezes Shorts  2021/01/20 12:44:10 CNA Finance
CLBS stock is squeezing the shorts out of their positions following an announcement of a patient treated in a Phase 2b trial.
   Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021  2021/01/06 13:30:00 GlobeNewswire
BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Embryonic Stem Cell Market to see Huge Growth by 2025 | BioTime, Caladrius Biosciences, Geron  2020/11/23 11:01:45 OpenPR
Latest released the research study on Global Embryonic Stem Cell Market, offers a detailed overview of the factors influencing the global business scope. Embryonic Stem Cell Market research report shows the latest market insights, current situation analysis with upcoming trends
   Embryonic Stem Cell Market to see Huge Growth by 2025 | BioTime, Caladrius Biosciences, Geron  2020/11/23 11:01:45 OpenPR
Latest released the research study on Global Embryonic Stem Cell Market, offers a detailed overview of the factors influencing the global business scope. Embryonic Stem Cell Market research report shows the latest market insights, current situation analysis with upcoming trends
   Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020  2020/11/10 13:30:00 GlobeNewswire
BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November  2020/11/04 13:30:00 GlobeNewswire
BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors  2020/11/02 13:30:00 GlobeNewswire
BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Bio launches CLBS119 study to repair COVID-19-induced lung damage (NASDAQ:CLBS)  2020/10/08 12:34:31 Seeking Alpha
Caladrius Biosciences (NASDAQ:CLBS) has opened its proof-of-concept study of CLBS119 (peripheral blood-derived autologous CD34+ cells) as a treatment and r
   Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020  2020/11/10 13:30:00 GlobeNewswire
BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November  2020/11/04 13:30:00 GlobeNewswire
BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors  2020/11/02 13:30:00 GlobeNewswire
BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   Caladrius Bio launches CLBS119 study to repair COVID-19-induced lung damage (NASDAQ:CLBS)  2020/10/08 12:34:31 Seeking Alpha
Caladrius Biosciences (NASDAQ:CLBS) has opened its proof-of-concept study of CLBS119 (peripheral blood-derived autologous CD34+ cells) as a treatment and r
   Caladrius Biosciences to Present at the BIO Investor Forum Digital  2020/10/06 20:05:00 GlobeNewswire
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラドリアス・バイオサイエンス CLBS Caladrius Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)